Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
← catalyst calendarNCT07252232 · readout in 995 d
Sponsored by Revolution Medicines, Inc. (industry) · RVMD — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
500estimated
Sites
60
Countries
France, Germany, Italy +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-15 | actual | When the study began enrolling |
| Primary completion | 2029-05-10 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-07-10 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pancreatic Cancer
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
- Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
- Resected Pancreatic Adenocarcinoma
Intervention
- Drug: daraxonrasib
Primary outcome
what the primary-completion date above is the date OFDisease-Free Survival (DFS) per Investigator
measured Up to approximately 5 years
Permalink · RVMD's whole pipeline · Catalyst calendar · Every registered study · What changed